Discover insights from Nu Skin's Q4 2024 earnings call, highlighting revenue growth, innovation, and 2025 strategic priorities.

Nu (NU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

We recently compiled a list of the Jim Cramer Shed Light on These 10 Stocks. In this article, we are going to take a look at ...

In a report released today, Anthony Vendetti from Maxim Group reiterated a Buy rating on Clinigence Holdings (NUTX – Research Report), with a ...

Nucor’s long-term growth supported by nearshoring and megatrends. Read why NUE stock is upgraded to a BUY with a $152 target ...